Moderate to Vigorous Physical Activity as a Digital Biomarker

MVPA is the time a person spends moving at moderate or vigorous intensity. It is the activity measure public health guidelines are written in, and accelerometers estimate it directly.

Status
Validated
Unit
minutes/day
Data type
Duration
Sensor
Accelerometer
Worn
Multiple

Evidence maturity

Graded with the V3 framework: whether the sensor measures accurately, whether the algorithm has been validated against a reference standard, and whether the measure has been shown to matter clinically.

Verification
Established
Analytical validation
Emerging
Clinical validation
Established

Technically mature and clinically meaningful, but analytically fragile: intensity classification depends entirely on the cut-points and wear location chosen, so MVPA values are rarely comparable across studies with different processing pipelines.

What is Moderate to Vigorous Physical Activity

Moderate to vigorous physical activity, usually shortened to MVPA, is the time a person spends moving at an intensity of roughly three metabolic equivalents or more. Brisk walking sits at the lower boundary, running well above it. MVPA matters because it is the currency of public health guidance: the World Health Organization recommends adults accumulate 150 to 300 minutes of moderate activity, or 75 to 150 minutes of vigorous activity, each week. Where step count answers how much someone moved, MVPA answers how hard. The two often diverge, and a participant can accumulate a respectable step total almost entirely below the moderate threshold. As a digital biomarker, MVPA converts a guideline written for populations into a measurable daily quantity for an individual participant, which is why it appears as a primary endpoint in trials testing whether an intervention actually changes how hard people move.

How it is measured

Accelerometers estimate intensity from the magnitude of body acceleration. Older pipelines convert raw acceleration into proprietary counts per minute and apply published cut-points, such as the Freedson or Troiano thresholds, to classify each epoch as sedentary, light, moderate or vigorous. Newer pipelines work from raw acceleration in gravitational units, most commonly the Euclidean norm minus one, which is comparable across device brands in a way counts are not. Hip and thigh placements track ambulatory intensity most faithfully; wrist placement is far more practical for long wear but needs its own thresholds. The reference standard is indirect calorimetry, which measures oxygen consumption directly. Note that the definition itself changed: guidelines before 2018 required activity to be accumulated in bouts of at least ten minutes, and current guidance counts all minutes, so older and newer studies are not directly comparable.

Clinical use

MVPA appears across trials where the question is whether an intervention changes activity intensity rather than volume. It is used in musculoskeletal and rheumatological studies, in heart failure and cardiac rehabilitation, in multiple sclerosis, and in metabolic trials where the intended mechanism runs through exercise. In the public DiMe endpoint library, MVPA is registered as a primary endpoint in several trials, more than most activity measures relative to how often it is used at all. Behaviour change and rehabilitation programmes commonly define success as a shift of participants across a guideline threshold rather than as a continuous minute change, because crossing the threshold carries an interpretation that a raw minute count does not. Studies typically pair MVPA with a self-reported activity questionnaire so that measured intensity can be read against perceived exertion.

Regulatory status

No standalone regulatory qualification to date. MVPA endpoints are written into registered trial protocols, including as primary outcomes, and the measure is anchored to World Health Organization physical activity guidelines rather than to a regulatory qualification.

Limitations

Cut-point dependence is the central problem. The same raw data classified with different thresholds can produce MVPA estimates that differ by a factor of two or more, so values are not comparable across studies unless the processing pipeline matches. Wrist-worn devices further complicate this, since arm movement is a poor proxy for whole-body intensity. Activities that load the body without moving it much, such as cycling, carrying loads or walking uphill, are systematically under-classified. Any study reporting MVPA should state its device, wear location, epoch length and cut-points, and any comparison that does not match on all four should be treated with caution.

References

  • Bull FC, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020. pubmed.ncbi.nlm.nih.gov
  • Troiano RP, et al. Physical activity in the United States measured by accelerometer. Med Sci Sports Exerc. 2008. pubmed.ncbi.nlm.nih.gov
  • Migueles JH, et al. Accelerometer data collection and processing criteria to assess physical activity and other outcomes: a systematic review and practical considerations. Sports Med. 2017. pubmed.ncbi.nlm.nih.gov
  • Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and Applications accelerometer. Med Sci Sports Exerc. 1998. pubmed.ncbi.nlm.nih.gov
Devices that capture it
Related instruments

Objective counterpart of self-reported activity questionnaires such as the SQUASH and the Physical Activity Scale for the Elderly, which ask participants to recall intensity that accelerometers measure directly.

Use case
Monitoring · Response
Collect Moderate to Vigorous Physical Activity and other digital biomarkers in one workflow. Or turn your research into a new digital biomarker?
Capture accelerometer derived activity intensity alongside patient reported outcomes in a single study workflow.

Collect your digital biomarker data in no time all under your own brand

Collect meaningful digital biomarker data from your patients with ease. Our platform connects with wearables, smartphones, and other digital health devices, helping you capture continuous, real world data for research or clinical use all within your own branded experience.

Learn More

Connect your Data Sources

Connect wearables, smartphones, and digital health devices to collect relevant biomarker data directly from your patients.
Learn More
We Guide

Collect Data Continuously

Capture passive and active digital biomarker data such as activity, sleep, heart rate, mobility, and other vital signals over time.
Learn More

Collect the Data that Matters

Collect the digital health data most relevant to your research or clinical program. Choose the measurements and data points that support your specific study objectives and use case.
Learn More

Monitor the Full Patient Journey

Collect longitudinal biomarker data throughout the patient journey, from onboarding and baseline assessment to ongoing monitoring and follow up.
Learn More
Build your own biomarker, gather
evidence and commerclise
support screenshot
Pallete Paints

Rapidly design and configure complex studies in one place.

Set up your study without the technical friction. Easily define and configure all the critical data points you need to collect from patient reported forms and clinical tests to remote wearables using our intuitive, centralised platform.
Clinical Trial Builder

Capture unified, multimodal data with automated workflows.

Utilise WeGuide Engage to build your required dataset effortlessly. Keep participants and clinicians actively involved through automated prompts, ensuring high compliance and consistent data capture across all modalities.
We Guide
We Guide
Toggle Right

Evaluate clinical algorithms instantly with AI powered tools.

Bypass the technical bottlenecks with our biomarker development studio. Seamlessly create, score, and evaluate complex algorithms with the click of a button, turning raw data into validated insights without bespoke coding.
We Guide

Distribute directly via our Class IIb certified platform.

Seamlessly transition from research to revenue. Commercialise your digital biomarker instantly on our regulatory approved infrastructure, making it immediately available for pharma, clinical trials, and real-world interventions.